pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
  1. pharmadog
  2. ›drugs
  3. ›Udenyca
drug
save

pegfilgrastim

Marketedupdated 6mo ago
by Accord Biopharma Inc
Approved
community read0 votes

🐶 often sniffed alongside

top 8
  • tagApproval10 co-mentions · 5 sources
  • drugSTIMUFEND8 co-mentions · 4 sources
  • companyFresenius Kabi USA LLC4 co-mentions · 4 sources
  • drugRNS-604 co-mentions · 4 sources
  • companyAccord Biopharma Inc2 co-mentions · 1 sources
  • tagRecall2 co-mentions · 1 sources
  • drugARMLUPEG2 co-mentions · 1 sources
  • companyLupin Ltd1 co-mentions · 1 sources

all catalysts(0)

nothing on the calendar yet

Trials studying pegfilgrastim

  • phase2Molecularly Stratified Trial for Newly Diagnosed Infant-Type Hemispheric Gliomanot yet recruitingn=50
  • phase2Neoadjuvant Intra-tumoral RP2 and FLOT in Gastroesophageal Adenocarcinomanot yet recruitingn=34
  • phase1Study of Captisol Enabled Melphalan and Pharmacokinetics for Patients With Multiple Myeloma or Light Chain Amyloidosis That Are Receiving an Autologous Transplant.active not recruitingn=46
  • phase2FOR46 in Combination With Enzalutamide in Patients With Metastatic Castration Resistant Prostate Canceractive not recruitingn=44
  • phase2ctDNA-Guided Therapy for Relapsed/Refractory Hodgkin Lymphomarecruitingn=38
  • phase2Trial of Single Protein Encapsulated Doxorubicin, SPEDOX-6 in Advanced Malignanciesrecruitingn=67
  • phase2Etoposide, Prednisone, Vincristine, Cyclophosphamide, and Doxorubicin (DA-EPOCH) With or Without Rituximab Plus Recombinant Erwinia Asparaginase (JZP458) for the Treatment of Newly Diagnosed Ph Negative B-Acute Lymphoblastic Leukemia or T Acute Lymphoblastic Leukemiarecruitingn=30
  • phase2Entrectinib as a Single Agent in Upfront Therapy for Children <3 Years of Age With NTRK1/2/3 or ROS1-FUSED CNS Tumorsrecruitingn=52

News(1)

  • Coherus cuts 30% of staffers, Gyre makes post-acquisition layoffs
    Coherus is narrowing its pipeline projects while Gyre reorganizes after an acquisition, with both biotechs conducting workforce reductions.
    biospace · 6d ago
brand
Udenyca
generic
pegfilgrastim-cbqv
indication
Febrile Neutropenia
phase
marketed
Data sources
ClinicalTrials.gov
last refreshed 5h ago
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?